Danone Exits Stake in Lifeway Foods

Why It Matters

The exit ends a two‑decade, litigation‑laden partnership and frees Danone to invest in its own kefir brands, while Lifeway gains independence to capitalize on booming probiotic demand. This shift could reshape competitive dynamics in the fast‑growing kefir market.

Key Takeaways

• Danone sells its 22.7% Lifeway stake at $19.50 per share.
• Sale price is $7.50 below Danone’s 2024 $27 acquisition offer.
• Lifeway’s quarterly sales topped $60 million, driven by kefir demand.
• Danone shifts focus to its own kefir line, expanding in Europe.

Pulse Analysis

The relationship between Danone and Lifeway Foods has been anything but smooth. For more than 20 years Danone held a minority stake in the kefir pioneer, repeatedly flirting with full acquisition only to back away amid legal battles and accusations of corporate bullying. The latest move—selling the 22.7% holding at $19.50 a share—marks a definitive break, capping a saga that saw lawsuits over share issuances and a stalled 2025 takeover attempt. By exiting, Danone clears a long‑standing distraction and can reallocate capital toward internal growth.

Kefir’s ascent has been propelled by consumer focus on gut health and the rise of GLP‑1 weight‑loss drugs, which have boosted demand for probiotic‑rich beverages. Lifeway has ridden that wave, posting its first $60 million‑plus quarterly revenue run‑rate, a milestone that underscores the category’s scalability. At the same time, Danone has been quietly building its own kefir franchise, launching Activia kefir in the U.K. in 2024 and rapidly expanding across Europe. The dairy giant’s statement that kefir products are “flying off the shelves” signals confidence that its in‑house brand can capture market share without relying on external partnerships.

Strategically, Danone’s divestiture frees it to double down on brand‑owned kefir, potentially accelerating product launches and supply‑chain efficiencies. For Lifeway, independence removes a hostile shareholder and may enable more aggressive expansion or strategic alliances. Investors will watch how the two companies allocate the freed capital: Danone could boost marketing spend or pursue acquisitions in complementary plant‑based segments, while Lifeway might invest in production capacity to meet surging demand. The reshuffle could intensify competition, prompting smaller players to differentiate through flavor innovation or functional claims, ultimately benefiting consumers seeking probiotic options.